Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

Paused · Phase 2

Conditions studied: Soft Tissue Sarcoma

In brief

This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas. 30 participants with soft tissue sarcoma will be enrolled and can expect to be on study for up to 5 years.

Key facts

Study ID

NCT05109494

Run by

University of Wisconsin, Madison

People needed

30

Starts

2022-04-06

Expected to finish

2028-11-01

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy proven soft tissue sarcoma of the extremity, trunk, or head and neck
• No prior sarcoma-directed chemotherapy or radiotherapy
• Age ≥ 18 years
• Karnofsky performance status ≥ 60
• Able to understand and sign an informed consent
• Life expectancy of greater than 12 weeks
• Hypofractionated or conventionally fractionated radiotherapy using Intensity Modulated Radiation Therapy (IMRT) are both deemed feasible and safe neoadjuvant treatments, at the treating physician's discretion
• Operable disease and medically fit for surgery, based on the opinion of the consulting surgeon; surgery within 5-14 days of completion of radiation therapy (RT)
• Adequate bone marrow function as defined by absolute neutrophil count > 500/mcL, hemoglobin > 8 g/dL, platelets > 50,000/mcL; adequate renal function as defined by creatinine clearance > 30 mL/min

You may not qualify if…

• Pregnant
• Unable to undergo imaging or positioning necessary for radiotherapy planning

Where it is running

• University of Wisconsin Hospital and Clinics — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.